Evidence map›Paper›PMID 37327118›Full record

ArticleBlood advances2023

Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia.

Sanam Shahid, Nicholas Ceglia, Jean-Benoît Le Luduec, Andrew McPherson, Barbara Spitzer, Theodota Kontopoulos, Viktoria Bojilova, M Kazim Panjwani, Mikhail Roshal, Sohrab P Shah and 3 more

Abstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sanam ShahidDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-4281-4910
Nicholas CegliaMemorial Hospital Research, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9387-103X
Jean-Benoît Le LuduecImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-1046-2941
Andrew McPhersonDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-5654-5101
Barbara SpitzerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-1603-1381
Theodota KontopoulosImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2054-4112
Viktoria BojilovaMemorial Hospital Research, Memorial Sloan Kettering Cancer Center, New York, NY.
M Kazim PanjwaniImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-2305-1164
Mikhail RoshalDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Sohrab P ShahDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6402-523X
Omar Abdel-WahabDepartment of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, New York, NY.ORCID 0000-0002-3907-6171
Benjamin GreenbaumDepartment of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6153-8793
Katharine C HsuImmunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2827-5324

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Although allogeneic hematopoietic cell transplant (allo-HCT) is curative for high-risk pediatric acute myeloid leukemia (AML), disease relapse remains the primary cause of posttransplant mortality. To identify pressures imposed by allo-HCT on AML cells that escape the graft-versus-leukemia effect, we evaluated immune signatures at diagnosis and posttransplant relapse in bone marrow samples from 4 pediatric patients using a multimodal single-cell proteogenomic approach. Downregulation of major histocompatibility complex class II expression was most profound in progenitor-like blasts and accompanied by correlative changes in transcriptional regulation. Dysfunction of activated natural killer cells and CD8+ T-cell subsets at relapse was evidenced by the loss of response to interferon gamma, tumor necrosis factor α signaling via NF-κB, and interleukin-2/STAT5 signaling. Clonotype analysis of posttransplant relapse samples revealed an expansion of dysfunctional T cells and enrichment of T-regulatory and T-helper cells. Using novel computational methods, our results illustrate a diverse immune-related transcriptional signature in posttransplant relapses not previously reported in pediatric AML.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteChildHistocompatibility Antigens Class IIHumansRecurrenceTransplantation, HomologousHistocompatibility Antigens Class II

Identifiers

PMID37327118
PMCPMC10471937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.